Search | Clinical Trials Finder

Conditions: Pancreatic Insufficiency
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 30 Years and older
Enrollment: 202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Sitagliptin, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Insufficiency, Cystic Fibrosis
Interventions: Omeprazole 20mg Capsule, Placebo oral capsule; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 12 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions: MS1819, Porcine PERT; Drug
Lead sponsor: Entero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Long Beach, California • Altamonte Springs, Florida • Miami, Florida + 7 more

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Neuroendocrine Tumor (NET)
Interventions: Structured Lipid Medical Food; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions: Liprotamase Powder for Oral Solution; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 28 Days and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 21
States / cities: Little Rock, Arkansas • Orange, California • Aurora, Colorado + 17 more

Conditions: Exocrine Pancreatic Insuficiency
Interventions: Fecal Fat; Diagnostic Test
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: 7 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Aurora, Colorado • New York, New York • Cincinnati, Ohio + 5 more

Conditions: Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions: Placebo, EUR-1008 (APT-1008) High Dose, EUR-1008 (APT-1008) Low Dose; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 6 more

Conditions: Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions: Allogeneic Bone Marrow Transplantation, Anti-Thymocyte Globulin, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Treosulfan, Umbilical Cord Blood Transplantation; Procedure · Biological · Drug + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 49 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 6
States / cities: Aurora, Colorado • Portland, Oregon • Nashville, Tennessee + 2 more

Conditions: Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions: venipuncture, Questionnaires, Additional Sample Collections; Other · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years and older
Enrollment: 120,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Exocrine Pancreatic Insufficiency (EPI), Pancreatitis
Interventions: RELiZORB; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pancreatic Insufficiency, Cystic Fibrosis, Digestive System Diseases, Lung Diseases, Respiratory Tract Diseases
Interventions: Burlulipase, Placebo (Caramel in sterile water); Drug
Lead sponsor: Nordmark Arzneimittel GmbH & Co. KG; Industry
Eligibility: 12 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 9
States / cities: Jacksonville, Florida • Pensacola, Florida • Iowa City, Iowa + 6 more

Conditions: Chronic Pancreatitis, Recurrent Acute Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions: Pancreatic Enzyme Replacement Therapy, Placebo, MBT1, MBT 2; Drug · Diagnostic Test
Lead sponsor: Anna Evans Phillips; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Exocrine Pancreatic Insufficiency
Interventions: ANG003; Drug
Lead sponsor: Anagram Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 16 more

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008), Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions: Liprotamase, porcine PERT; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 28
States / cities: Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 24 more

Conditions: Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions: Pancrelipase Delayed Release, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 10
States / cities: Iowa City, Iowa • Louisville, Kentucky • Boston, Massachusetts + 6 more

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Ultrase® MT20; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Cleveland, Ohio • Hershey, Pennsylvania

Conditions: Pancreatic Adenocarcinoma
Interventions: Pancrelipase; Drug
Lead sponsor: Andrew Hendifar, MD; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Exocrine Pancreatic Insufficiency (EPI)
Interventions: Pancrelipase, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 21 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 27 more

Conditions: Cystic Fibrosis
Interventions: Pancrelipase Delayed Release, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Exocrine Pancreatic Insufficiency
Interventions: VIOKASE 16; Drug
Lead sponsor: Axcan Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Gainesville, Florida • Mayo Clinic- Rochester, Minnesota

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Pentadecanoic acid (PA) and Triheptadecanoin (THA); Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis
Interventions: Pancrelipase; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 13
States / cities: Los Angeles, California • Ventura, California • Jacksonville, Florida + 9 more

Search by objective public record fields.

Pancreatic Insufficiency Secondary to Tobacco Exposure

Effect of Chronic Incretin-based Therapy in Cystic Fibrosis

Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

Nutrition Intervention for Pancreatic Cancer

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis

Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients

Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis

Phase 1 Study to Assess Safety and Efficacy of ANG003

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)

Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis